skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility

Review

(4023) Views  (2327) Full article downloads

Authors: David T Nash, Michael S McNamara

Published Date October 2009 Volume 2009:2 Pages 39 - 54
DOI: http://dx.doi.org/10.2147/IBPC.S4623

David T Nash1, Michael S McNamara2

1Syracuse Preventive Cardiology, Syracuse, New York, USA; 2Oxford PharmaGenesis Inc., Newtown, Pennsylvania, USA

Abstract: The morbidity and mortality benefits of lowering blood pressure (BP) in hypertensive patients are well established, with most individuals requiring multiple agents to achieve BP control. Considering the important role of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of hypertension, a key component of combination therapy should include a RAAS inhibitor. Angiotensin receptor blockers (ARBs) lower BP, reduce cardiovascular risk, provide organ protection, and are among the best tolerated class of antihypertensive therapy. In this article, we discuss two ARB combinations (valsartan/hydrochlorothiazide [HCTZ] and amlodipine/valsartan), both of which are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy and as initial therapy in patients likely to need multiple drugs to achieve BP goals. Randomized, double-blind studies that have assessed the antihypertensive efficacy and safety of these combinations in the first-line treatment of hypertensive patients are reviewed. Both valsartan/HCTZ and amlodipine/valsartan effectively lower BP and are well tolerated in a broad range of patients with hypertension, including difficult-to-treat populations such as those with severe BP elevations, prediabetes and diabetes, patients with the cardiometabolic syndrome, and individuals who are obese, elderly, or black. Also discussed herein are patient-focused perspectives related to the use of valsartan/HCTZ and amlodipine/valsartan, and the rationale for use of single-pill combinations as one approach to enhance patient compliance with antihypertensive therapy.

Keywords: amlodipine, combination therapy, hydrochlorothiazide, hypertension, valsartan








Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Cuff inflation during ambulatory blood pressure monitoring and heart rate
Amlodipine and valsartan as components of a rational and effective fixed-dose combination
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exforge® (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact
Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility
Isolated pulmonary veno-occlusive disease and pulmonary arterial thrombosis in systemic sclerosis – a lethal combination
Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University